Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5056668 | 0.83 | QPCT (0.37) | HPGDTSHRGRM5PLA2G7DPP4 | |
| SCHEMBL12471409 | 0.77 | ALOX15 (0.37) | HPGDTSHRGRM5 | |
| SCHEMBL2948183 | 0.75 | ALDH1A1 (0.37) | HPGDTSHRGRM5PLA2G7TP53 | |
| SCHEMBL5134298 | 0.75 | MAPT (0.34) | HPGDTSHRGRM5PLA2G7MAPT | |
| SCHEMBL3306433 | 0.73 | PLA2G7 (0.36) | HPGDTSHRGRM5PLA2G7DPP4 | |
| SCHEMBL660060 | 0.69 | CYP19A1 (0.42) | — | |
| SCHEMBL29868595 | 0.69 | CYP19A1 (0.42) | — | |
| SCHEMBL5057057 | 0.69 | BRD4 (0.34) | — | |
| SCHEMBL660731 | 0.68 | PLA2G7 (0.39) | PLA2G7DPP4 | |
| SCHEMBL20555017 | 0.68 | PLA2G7 (0.39) | PLA2G7DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214815-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2012-08-23 | — | — | US | claimed |
| US-20120196866-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2012-08-02 | — | — | US | claimed |
| EP-1891042-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB Pharma, S.A. (BE) | 2008-02-27 | — | — | EP | claimed |
| WO-2006128693-A2 | 2 -OXO-I -PYRROLIDINE DERIVATIVES/ PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA, S.A. (BE) | 2006-12-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214815-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | HPGD 172/4885TSHR 4142/4885GRM5 2300/4885 |
| US-20120196866-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | HPGD 172/4885TSHR 4142/4885GRM5 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.